Can non-profits beat antibiotic resistance and soaring drug costs?

In November, zoliflodacin, an oral antibiotic, was found effective against gonorrhoea, a sexually transmitted disease, and a new antifungal drug, fosravuconazole, was found safe and effective in treating fungal mycetoma. These drugs were developed by non-profit organizations, GARDP and DNDi, to fill a gap in drug development and testing. The success of these trials suggests that non-profits can help solve drug access issues and combat drug-resistant microbes, which contribute to nearly five million deaths annually. These achievements demonstrate the potential of non-profits in combating antimicrobial resistance.